Candidiasis, also known as thrush or moniliasis, is a fungal infection caused by a yeast (a type of fungus) called Candida. Candida naturally lives on the skin as well as in warm, moist areas of the body such as the mouth and gut. However, sometimes it can lead to an overgrowth leading to infection. Candidiasis can cause an oral thrush, a vaginal yeast infection, or a diaper rash in babies. The infections range from superficial, such as oral or vaginal infections, to systemic and potentially life-threatening candidemia. Factors such as a weakened immune system from medical conditions, immunosuppressive therapy, use of antibiotics or hormonal birth control increase the risk of developing candidiasis.

The global candidiasis market is estimated to be valued at US$ 1134.49 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Increasing prevalence of opportunistic infections in HIV/AIDS patients and growing cancer population undergoing chemotherapy are the major drivers boosting growth of the candidiasis market. According to UNAIDS, there were approximately 37.7 million people living with HIV at the end of 2018 and opportunistic infections such as candidiasis are highly prevalent in patients with suppressed immune system. Furthermore, chemotherapy treatment leaves patients vulnerable to fungal infections due to low white blood cells count. The introduction of antifungal drugs such as azoles, echinocandins and polyenes offers effective treatment options against invasive and non-invasive fungal infections. This in turn is expected to boost the candidiasis market growth during the forecast period.

SWOT Analysis

Strength: The candidiasis market has a large patient pool that is suffering from the disease globally. Growing prevalence of HIV/AIDS and increasing hospital-acquired infections are major drivers. Furthermore, rising healthcare spending and availability of many treatment options provide impetus.

Weakness: However, lack of awareness about various symptoms of candidiasis poses a challenge. Moreover, high costs associated with treatment and drugs can restrain the market's growth to some extent.

Opportunity: Growing geriatric population susceptible to Candida infections creates opportunities. Furthermore, ongoing research & development activities to develop novel antifungal drugs will likely open new avenues. Rising healthcare infrastructure in emerging nations also presents opportunities.

Threats: Existing players face tough competition due to presence of generic drugs. Additionally, side effects associated with various antifungal drugs and threat of drug resistance can negatively impact the candidiasis market.

Key Takeaways

The Global Candidiasis Market Share is expected to witness high. The global candidiasis market is estimated to be valued at US$ 1134.49 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2024 to 2031.

Regional analysis related content comprises The North America candidiasis market is expected to dominate during the forecast period due to growing prevalence of associated risk factors and increasing healthcare spending. Europe holds the second largest market share owing to rising research & development activities.

Key players related content comprises Key players operating in the candidiasis market are Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc., among others.

Get more insights on this topic:  https://www.newswirestats.com/candidiasis-market-market-size-and-share-analysis-growth-trends-and-forecasts/
 
Explore more information on this topic, Please visit: https://whotimes.com/hashgraph-the-next-generation-distributed-ledger-technology/